Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration

JAMA

Volumn 280, Issue 17, 1998, Pages 1497-1503

  Detels, Roger ^a,g   Muñoz, Alvaro ^c   McFarlane, Glen ^c   Kingsley, Lawrence A ^d   Margolick, Joseph B ^c   Giorgi, Janis ^b   Schrager, Lewis K ^e   Phair, John P ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CLARITHROMYCIN; DAPSONE; DELAVIRDINE; DIDANOSINE; FLUCONAZOLE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PENTAMIDINE; PROTEINASE INHIBITOR; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; SULFAMETHOXAZOLE; TRIMETHOPRIM; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DEATH; DRUG EFFICACY; DRUG POTENCY; HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL;

EID: 0032483690     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.17.1497     Document Type: Article

References (34)

1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
2. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
3. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995;333:1534-1539.
4. Stein D, Drusan G, Steigbigel R, et al. Two year follow-up of patients treated with indinavir 800 mg q 8 h. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 100.
5. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
6. 3. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 207.
7. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962-1969.
8. Hammer SC, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997; 337:725-733.
9. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
10. Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths, and prevalence - United States, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:155-173.
11. Sorvillo F, Kerndt PR, Odem S, Castillon M, Carruth A, Contreras R. Use of protease inhibitors among persons with AIDS in Los Angeles County. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:179-181.
12. Chiasson MA, Berenson L, Li W, Schwartz S, Mojica B, Hamburg M. Declining AIDS mortality in New York City. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 376.
13. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318.
14. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ. 1997;315:1194-1199.
15. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998; 279:450-454.
16. Chmiel JS, Detels R, Kaslow RA, Van Raden M, Kingsley LA, Brookmeyer R. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am J Epidemiol. 1987;126:568-577.
17. Detels R, Phair JP, Saah AJ, et al. Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study. J Epidemiol. 1992;2(suppl):S11-S19.
18. Kingsley LA, Detels R, Kaslow R, et al. Risk factors for seroconversion to human immunodeficiency virus amongmale homosexuals. Lancet. 1987; 1:345-349.
19. Kingsley LA, Zhou SY, Bacellar H, et al. Temporal trends in human immunodeficiency virus type 1 seroconversion, 1984-1989: a report from the Multicenter AIDS Cohort Study (MACS). Am J Epidemiol. 1991;134:331-339.
20. Muñoz A, Sabin C, Phillips AN. The incubation period of AIDS. AIDS. 1997;11(suppl A):S69-S76.
21. Gail MH. Use of observational data for evaluating AIDS therapies. In: Finkelstein DM, Schoenfeld DA, eds. AIDS Clinical Trials. New York, NY: John Wiley & Sons Inc; 1995:403-422.
22. Muñoz A, Hoover DR. Use of cohort studies for evaluating AIDS therapies. In: Finkelstein DM, Schoenfeld DA, eds. AIDS Clinical Trials. New York, NY: John Wiley & Sons Inc; 1995:423-446.
23. Centers for Disease Control and Prevention. Report of NIH Panel to define principles of therapy of HIV infection and guidelines for the use of anti-retroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep. 1998;47 (RR-5):1-82.
24. Clayton D, Hills M. Statistical Models in Epidemiology. New York, NY: Oxford University Press Inc; 1993.
25. Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med. 1992;11:1871-1879.
26. Muñoz A, Sunyer J. Comparison of semiparametric and parametric survival models for the analysis of bronchial responsiveness. Am J Respir Crit Care Med. 1996;154:S234-S239.
27. Diggle PJ, Lian KY, Zeger SL. Analysis of Longitudinal Data. New York, NY: Oxford University Press Inc; 1994.
28. Muñoz A, Xu J. Models for the incubation of AIDS and variations according to age and period. Stat Med. 1996;15:2459-2473.
29. + T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
30. Veugelers PJ, Cornelisse PG, Craib KJ, et al. Models of survival in HIV infection and their use in the quantification of treatment benefits. Am J Epidemiol. 1998;148:487-496.
31. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
32. Detels R, Muñoz A, Peng Y, Graham N, Mellors J, Phair J. Early versus deferred zidovudine monotherapy: impact on AIDS-free time and survival in the Multicenter AIDS Cohort Study. Antiviral Ther 1997;2:21-29.
33. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322:941-949.
34. Barken SE, Melnick SL, Preston-Martin, et al. The Women's Interagency HIV Study. Epidemiology. 1998;9:117-125.